Document Detail


Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study.
MedLine Citation:
PMID:  15138895     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The changes of theta activity (3.5-7 Hz) in the quantitative electroencephalography (QEEG) and serum clozapine levels and their correlation with clinical response, measured by the Positive and Negative Syndrome Rating Scale (PANSS) for schizophrenia, were examined prospectively in 16 patients suffering from schizophrenia during 18 weeks of clozapine (CLO) treatment. METHODS: Evaluations were performed on five occasions: before the initiation of CLO treatment at baseline and after 1, 3, 10, and 18 weeks of treatment. Doses of CLO starting from 50 mg/day were determined on the basis of clinical response. In the PANSS subscales for positive and negative symptoms, a significant (P < 0.05) improvement was observed after the first week, and in the subscale for general symptoms, improvement was seen after three weeks of treatment with CLO. A significant increase in theta power (P < 0.01) was found after three weeks of CLO treatment in the electrodes over the fronto-central scalp area, most distinctly in the midline. RESULTS: After three weeks we observed significant inverse correlations between the theta power increase and the changes in PANSS subscales for negative (P < 0.01) and positive (P < 0.05) symptoms, and after 10 weeks, between the theta power increase and the change in PANSS subscales for general (P < 0.05) and positive (P < 0.05) symptoms. After 18 weeks a trend of inverse correlation between the PANSS subscales for general and negative symptoms and the right and midline theta power increase was observed, but not with regard to positive symptoms. There were trends, but no significant correlations, between CLO treatment response and serum CLO levels. CONCLUSIONS: These findings indicate that the change in the theta frequency in QEEG and particularly in the midline electrodes over the fronto-central scalp area might be a more sensitive indicator for the evaluation of CLO treatment adequacy than the serum CLO level.
Authors:
Andres Gross; Sirkka-Liisa Joutsiniemi; Ranan Rimon; Björn Appelberg
Related Documents :
19906345 - Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a ...
17391345 - Disability associated with mood states and comparator conditions: application of the li...
18303965 - Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improveme...
36865 - Clinical usefulness of sodium amobarbital interviewing.
19692345 - Severity of baseline alcohol use as a moderator of brief interventions in the emergency...
8623975 - Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacopsychiatry     Volume:  37     ISSN:  0176-3679     ISO Abbreviation:  Pharmacopsychiatry     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-05-12     Completed Date:  2004-07-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8402938     Medline TA:  Pharmacopsychiatry     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  119-22     Citation Subset:  IM    
Affiliation:
Helsinki University Central Hospital, Department of Psychiatry, Helsinki, Finland. andres.gross@luukku.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / therapeutic use*
Clozapine / therapeutic use*
Drug Evaluation
Electroencephalography / classification,  drug effects*
Female
Humans
Longitudinal Studies
Male
Neurologic Examination
Prospective Studies
Psychiatric Status Rating Scales
Schizophrenia / drug therapy*,  physiopathology
Schizophrenic Psychology
Statistics, Nonparametric
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative...
Next Document:  Paroxetine in major depression: correlating plasma concentrations and clinical response.